PHASE 1 STUDY OF MRNA-2752, A LIPID NANOPARTICLE ENCAPSULATING MRNAS ENCODING HUMAN OX40L/IL-23/IL-36 γ , FOR INTRATUMORAL (ITU) INJECTION +/- DURVALUMAB IN ADVANCED SOLID TUMORS AND LYMPHOMA

¹Manish Patel, ²Antonio Jimeno, ³Ding Wang, ⁴Salomon Stemmer, ⁵Todd Bauer, ⁶Randy Sweis, ⁷Ravit Geva, ⁸Shivaani Kummur, ⁹Patrick Reagan, ¹⁰Ruth Perets, ¹¹Patricia LoRusso, ¹²Shilpa Gupta, ¹³Sima Zacharek, ¹³Andressa Laino, ¹³Oleg Milberg, ¹³Josh Frederick, ¹³Sheryl Chen, ¹³Stephanie Pascarella, ¹³William Randolph, ¹³Praveen Aanur, ¹³Lisa Johansen, ¹³Khanh Do, ¹³Robert Meehan, ¹⁴Ryan Sullivan*. ¹SCRI/Florida Cancer Specialists, Sarasota, FL, USA; ²University of Colorado Cancer Center, Aurora, CO, USA; ³Henry Ford Hospital, Detroit, MI, USA; ⁴Rabin Medical Center, Tel Aviv, Israel; ⁵Sarah Cannon Research Institute, Franklin, TN, USA; ⁶The University of Chicago, Chicago, IL, USA; ⁷Sourasky Medical Center, Tel-Aviv, Israel; ⁸Oregon Health and Science University, Portland, OR, USA; ⁹University of Rochester, Rochester, NY, USA; ¹⁰Rambam Medical Center and Technion, Haifa, Israel; ¹¹Yale School of Medicine, New Haven, USA; ¹²The Cleveland Clinic Foundation, Cleveland, OH, USA; ¹³Moderna Therapeutics, Cambridge, MA, USA; ¹⁴Massachusetts General Hospital, Boston, MA, USA

Background mRNA-2752 is a novel mRNA-based therapeutic agent encoding OX40L T cell co-stimulator, IL-23 and IL-36 γ pro-inflammatory cytokines. Preclinical data demonstrate synergy in combination with PD-L1 blockade.

Methods This study evaluated the safety and efficacy of ITu mRNA-2752 administered Q2W up to 7 doses as monotherapy (Arm A) or in combination with the PD-L1 inhibitor durvalumab (Arm B) in patients (pts) with palpable tumors or tumors accessible with image guidance. Biomarker analyses included IHC of immune markers, whole transcriptome assessments, and protein evaluations of IL-23, IL-36 γ and pro-inflammatory cytokines in pre- and post-treatment tumor biopsies and plasma. A PK/PD model was built to capture the IL-23 serum concentrations at the Q2W regimen to predict the exposure at the QW regimen to support an exploratory cohort.

Results As of 08April 2021, 49 pts were treated: Arm A (n=19) and Arm B (n=30) at doses ranging from 0.25 to 8mg Q2W. Treatment emergent adverse events (TEAEs) occurring in $\geq 10\%$ of pts included Gr 1/2 injection site erythema/pain/swelling, fever, chills, fatigue, AST/ALT increase, lumbar myalgia, and maculopapular rash. One DLT of cytokine release syndrome was seen at the 8mg dose in Arm B. A squamous-cell bladder cancer and DLBCL have achieved confirmed PRs on Arm B, ongoing for 23 and 16 cycles, respectively. Biomarker analyses show increased IL-23 and IL-36 γ protein expression, and their respective downstream cytokines IL-22 and IL-6, in tumor and plasma 6–24h after dosing; most cytokines assessed were elevated after treatment. Increased IFN γ and TNF α in tumor and plasma, sustained increases in interferon response genes including PD-L1 and markers of T cell infiltration, and activation in the TME (particularly in pts achieving a PR) indicate pro-inflammatory treatment effects with mRNA-2752 +/- durvalumab. PK/PD modeling showed the C_{max} of IL-23 serum concentration of mRNA-2752 at 8mg approached a plateau, and simulations showed increasing the dosing frequency from Q2W to QW vs. dose increase may have a greater effect on increasing drug exposure.

Conclusions ITu mRNA-2752 is safe and tolerable when combined with durvalumab. The recommended dose for expansion is 8mg mRNA-2752. Analyses of tumor and plasma biomarkers suggest a sustained treatment effect that includes elevated IFN γ , TNF α , and PD-L1 levels, providing rationale for combination therapy. Enrollment is ongoing in expansion cohorts of TNBC, urothelial cancer, lymphoma, immune-

checkpoint refractory melanoma and NSCLC. PK/PD modeling supports QW dosing which is being explored in cutaneous melanoma in the neoadjuvant setting.

Trial Registration NCT03739931

REFERENCES

- Hewitt SL, Bai A, Bailey D et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36 γ , and OX40L mRNAs. *Sci Transl Med*. 2019;11(477):1–15.

Ethics Approval The study was approved by the respective participating Institution's Ethics Board and conducted in accordance with the International Council for Harmonisation harmonised tripartite guideline E6(R1): Good Clinical Practice and all applicable government regulations.

Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

<http://dx.doi.org/10.1136/jitc-2021-SITC2021.539>